siRNA Nanoparticle Delivery for ARDS Inflammatory Gene Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute respiratory distress syndrome (ARDS) are ineffective, and there is a need for novel therapeutic approaches to address the underlying inflammatory response and prevent long-term effects.
Innovation Solution
The use of RNA interference-inducing compositions, specifically short interfering RNA (siRNA) or short hairpin RNA (shRNA), to downregulate expression of inflammatory mediators and receptors in pulmonary tissue, combined with the administration of regenerative mesenchymal stem cells to mitigate ARDS symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mechanical ventilation is used to treat ARDS, then respiratory support is provided, but the underlying inflammatory response is not addressed and mortality remains high
Solution Approach 1:
The patent extracts and targets specific inflammatory mediators (TNF-alpha, IL-1beta, IL-6) and their receptors in the lung tissue using siRNA molecules. By selectively silencing these specific genes responsible for the harmful inflammatory response, the treatment addresses the root cause of ARDS rather than just providing symptomatic respiratory support through mechanical ventilation.
Solution Approach 2:
The patent uses liposome-nanoparticle conjugates as intermediary carriers to deliver siRNA molecules to the lung tissue. These nanoparticles act as mediators that protect the siRNA from degradation, enable targeted delivery to inflammatory sites, and facilitate cellular uptake, thereby enhancing the effectiveness of gene silencing therapy.
2Ease of operation
If conventional treatments are used for ARDS, then standard care is provided, but no actual treatment of the syndrome itself has been proven effective
Solution Approach 1:
The patent changes the therapeutic parameter from conventional symptomatic treatment to targeted gene silencing therapy. By using siRNA molecules that specifically bind to and silence the mRNA of inflammatory mediators, the treatment fundamentally alters the disease process at the molecular level, providing proven therapeutic efficacy where conventional treatments have failed.
Solution Approach 2:
The patent employs a composite delivery system consisting of liposomes conjugated with nanoparticles that carry siRNA molecules. This composite material combines the advantages of liposomes (biocompatibility, targeted delivery) with nanoparticles (protection from degradation, enhanced cellular uptake), creating an effective therapeutic platform that overcomes the limitations of conventional single-modality treatments.
3Reliability
If gene silencing therapy is applied to reduce inflammatory response, then therapeutic effectiveness is improved, but new treatment methodology complexity increases
Solution Approach 1:
The siRNA molecules themselves possess the inherent ability to locate and bind to their complementary mRNA targets through base pairing. Once inside the cell, the RNA interference mechanism automatically processes the siRNA to silence the target gene without requiring external intervention or complex control systems, thereby simplifying the overall treatment methodology despite the advanced molecular mechanism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces the inflammatory response and promotes tissue repair, potentially improving respiratory function and reducing mortality associated with ARDS by selectively silencing target genes involved in the inflammatory process and providing regenerative cell populations.
Implementation Method 1
administering said patient a composition capable of inducing the process of RNA interference to one or more inflammatory mediators
Data Source
AI summary
Disclosed are treatment means, compositions of matter and protocols useful for suppression of acute respiratory disorder (ARDS) through induction of RNA interference in the pulmonary microenvironment alone and/or in conjunction with mucolytic and/or DNA disrupting agents. In one embodiment short interfering RNA (siRNA) is prepared which targets complement receptors C3R and/or C5R together with TNF-receptor, IL-6 receptor and/or TLR4 and TLR9. In some embodiments nanostilbene is utilized as a delivery vehicle for siRNA delivery.